UNCY — Unicycive Therapeutics, Inc.

UNCY closed at $3.89 (-1.27%) on Oct 23, 2026. Active shelf registration (S-3, Jun 2026). Float: 19.1M shares. Latest SEC filing: 8-K on Aug 12, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for UNCY in the TickerWise workspace.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 22
• Website: https://www.unicycive.com

Latest SEC filings for UNCY

• 2026-08-128-K
• 2026-08-1210-Q
• 2026-07-08SCHEDULE 13G/A
• 2026-07-028-K
• 2026-06-228-K
• 2026-06-16EFFECT
• 2026-06-058-K
• 2026-06-05S-3
• 2026-06-05S-3
• 2026-05-128-K

Latest UNCY news

• 2026-10-24UNCY DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY Read article
• 2026-10-22Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm Read article
• 2026-10-21UNCY FINAL DEADLINE: ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY Read article
• 2026-10-21UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky Read article
• 2026-10-20Unicycive Therapeutics, Inc. Investors Have Until November 2nd to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role Read article
• 2026-10-18UNICYCIVE DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY Read article
• 2026-10-14Unicycive Therapeutics, Inc. Class Action Reminder - Robbins LLP Encourages UNCY Investors to Contact the Firm About Their Rights Read article
• 2026-10-14Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit Read article

Related companies

• VRTX — Vertex Pharmaceuticals Incorporated
• MRNA — Moderna, Inc.
• REGN — Regeneron Pharmaceuticals, Inc.
• ARGX — argenx SE
• ALNY — Alnylam Pharmaceuticals, Inc.
• INSM — Insmed Incorporated
• RVMD — Revolution Medicines, Inc.
• UTHR — United Therapeutics Corporation

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.